All In MedTech

FDA Clearance Tracker · P910056-S032

enVista One Piece Hydrophobic Acrylic Intraocular Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 3, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 3, 2019

Approved

Time to decision

352 days

Received Jul 16, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P910056-S032
Device name
enVista One Piece Hydrophobic Acrylic Intraocular Lens
Applicant location
Irvine, CA
Received
Jul 16, 2018
Decided
Jul 3, 2019
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P910056

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

Approval for an alternate packaging configuration for the IOL along with the designation as Model MX60PL.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.